Oramed Pharmaceuticals, Inc.

As of September 11, 2025, Oramed Pharmaceuticals, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands, with a recent 17.31% monthly return, although it has underperformed over the past three years compared to the S&P 500.

As of May 15, 2025, Oramed Pharmaceuticals, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 0.64, an EV to EBITDA ratio of 2.81, and a -20.08% ROE, alongside significant underperformance compared to the S&P 500.

As of May 15, 2025, Oramed Pharmaceuticals, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 0.64, an EV to EBITDA ratio of 2.81, and a Return on Equity of -20.08%, alongside underperformance compared to the S&P 500.

As of March 2022, the management team of Oramed Pharmaceuticals, Inc. includes Kevin Rakin (Independent Chairman), Nadav Kidron (CEO), Miriam Kidron (Chief Scientific Officer), and several independent directors: Aviad Friedman, Xiaoming Gao, Arie Mayer, and Leonard Sank. They oversee the company's strategic direction and operations.

Oramed Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing oral treatments for diabetes. As of March 2025, it reported net sales of $2 million and a net loss of $8 million, with a market cap of $88.24 million.

As of Jun 18, Oramed Pharmaceuticals, Inc. has a market capitalization of 88.24 million, with net sales of 2.00 million and a net loss of 28.28 million over the last four quarters. Shareholder's funds are 146.26 million, and total assets amount to 155.28 million.